Table 3 Baseline (at the initiation of TDF treatment) characteristics associated with significant liver stiffness regression achievement after 90 (range: 36–154) months TDF monotherapy

Baseline LSM

0.106

1.066 (0.986–1.153)

Advanced fibrosis/cirrhosis

Cirrhosis

0.013

0.015

3.63 (1.310-10.1058)

14.824 (1.687-130.248)

0.024

0.811

5.169 (1.240–21.540)

1.356 (0.112–16.399)

Baseline ALT

0.627

1 (0.999–1.002)

Baseline HBV DNA

0.883

1(1–1)

Platelet x 10⁹ /L

0.031

1 (1–1)

Age

0.419

1.013 (0.981–1.047)

> 60 years old

0.54

1.312 (0.542–3.177)

Males

0.65

0.816 (0.338–1.972)

Parameters of metabolic syndrome

0.238

0.583 (0.238–1.428)

BMI

BMI ≥ 25

0.006

0.0001

0.830 (0.727–0.947)

0.019 (0.002–0.146)

0.592

0.001

0.949 (0.783–1.149)

0.014 (0.001–0.157)

Hypertension

0.5

1.382 (0.502–3.810)

Dyslipidemia

0.16

0.216 (0.026–1.828)

Diabetes

0.814

0.815 (0.148–4.475)

Smoking

0.444

1.533 (0.513–4.584)